Effect of μ-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells

Marianne Strazza1,2,3, Anupam Banerjee1,2,3, Aikaterini Alexaki1,2,3, Shendra R Passic1,2,3, Olimpia Meucci1,2,3,4, Vanessa Pirrone1,2,3, Brian Wigdahl1,2,3 and Michael R Nonnemacher1,2,3*

Abstract

Background: Approximately one-third of the AIDS cases in the United States have been attributed to the use of injected drugs, frequently involving the abuse of opioids. Consequently, it is critical to address whether opioid use directly contributes to altered susceptibility to HIV-1 beyond the increased risk of exposure. Previous in vitro and in vivo studies addressing the role of μ-opioid agonists in altering levels of the co-receptor CXCR4 and subsequent HIV-1 replication have yielded contrasting results. The bone marrow is believed to be a potential anatomical sanctuary for HIV-1.

Methods: The well-characterized CD34+CD38- human bone marrow–derived hematopoietic progenitor cell line TF-1 was used as a model to investigate the effects of the μ-opioid receptor–specific peptide DAMGO (D-Ala2, N-Me-Phe4, Gly5-ol-enkephalin) on CXCR4 expression as well as infection of undifferentiated human hematopoietic progenitor cells.

Results: The results revealed the presence of the μ-opioid receptor-1 isoform (MOR-1) on the surface of TF-1 cells. Furthermore, immunostaining revealed that the majority of TF-1 cells co-express MOR-1 and CXCR4, and a subpopulation of these double-positive cells express the two receptors in overlapping membrane domains. Three subpopulations of TF-1 cells were categorized based on their levels of surface CXCR4 expression, defined as non-, low-, and high-expressing. Flow cytometry indicated that treatment with DAMGO resulted in a shift in the relative proportion of CXCR4+ cells to the low-expressing phenotype. This result correlated with a >3-fold reduction in replication of the X4 HIV-1 strain IIIB, indicating a role for the CXCR4 high-expression subpopulation in sustaining infection within this progenitor cell line.

Conclusions: These experiments provide insight into the impact of μ-opioid exposure with respect to inhibition of viral replication in this human TF-1 bone marrow progenitor cell line model.

Keywords: μ-opioid receptor (MOR-1), DAMGO, Human immunodeficiency virus type 1 (HIV-1), Bone marrow, CXCR4
by upregulating CCR5 expression and inhibiting production of β-chemokines, endogenous CCR5 ligands [5].

Ongoing in vivo studies performed in the simian immunodeficiency virus (SIV)-infected rhesus macaque/model have yielded a better understanding of the impact of prolonged morphine exposure on HIV-1 pathogenesis. Prolonged morphine exposure increased viral replication [6,7], increased the number of SIV-infected T cells [8], accelerated disease progression and neuropathogenesis [7], increased the amount of plasma virus [6,7], and increased the incidence of mortality [7]. Despite these numerous studies, a direct link between an alteration in CXCR4 or CCR5 surface expression levels and quantity of plasma virus has not been established.

The μ-opioid receptor-1 isoform (MOR-1), the best characterized isoform of the μ-opioid receptor family, has been found on cellular subsets of the immune system, as well as cells of the central nervous system, including but not limited to neurons [9-11]. It is possible that reported inconsistencies in the literature regarding the expression profile of CXCR4 may be attributable to a cell type-specific regulation of this chemokine co-receptor by μ-opioids. This process in turn might translate into the differential ability of μ-opioids to modulate HIV-1 replication in divergent cellular populations. To investigate the effect of μ-opioids on CXCR4 expression in human bone marrow progenitor cells, the TF-1 cell line was used; it represents a model of susceptible CD34+/CD38- human hematopoietic progenitor cells that are blocked at an early stage of differentiation [12]. To begin experimentation in the TF-1 cell line, experiments were performed to assess levels of MOR-1 in these cells by western immunoblot analyses, flow cytometry, and immunofluorescence microscopy. To analyze the relative surface distribution of MOR-1 and CXCR4, immunofluorescence microscopy studies were also performed. Alterations in total CXCR4 protein levels in DAMGO-treated TF-1 cells were determined using western immunoblot analyses and surface expression levels were examined using flow cytometry.

We have previously demonstrated that, in addition to CXCR4, TF-1 cells express the primary HIV-1 receptor CD4 on their cell surface, thereby supporting productive infection by the HIV-1 X4-utilizing (X4) IIIB strain [13]. This observation prompted studies examining the consequence of DAMGO-mediated perturbation in CXCR4 levels on HIV-1 X4 replication in this human bone marrow–derived progenitor cell population.

**Results**

**Identification of MOR-1 in TF-1 cells**

Western immunoblot analysis confirmed the presence of MOR-1 protein within TF-1 cells, clearly demonstrating the existence of a specific protein species at approximately 50 KDa, the expected molecular mass of human MOR-1 (Figure 1A) [14]. As expected, the levels of MOR-1 in undifferentiated SH-SY5Y neuroblastoma cell lysates (positive control) were much higher than those observed in TF-1 lysates. In addition, the detection of MOR-1 was abrogated by preincubating the primary antibody with the MOR-1 blocking peptide. Blotting the membrane for β-actin confirmed equal loading in all lanes. Immunostaining of nonpermeabilized cells analyzed by flow cytometry (Figure 1B) and fluorescent microscopy (Figure 1C) clearly demonstrated that MOR-1 was expressed at the cell surface.

**Relative localization of MOR-1 and CXCR4**

To analyze the relative distribution of MOR-1 and CXCR4 at the cellular level, immunofluorescence studies on nonpermeabilized TF-1 cells was performed. CXCR4 and MOR-1 were shown to be co-expressed on the surface of a number of TF-1 cells. The majority of the cells quantitated (87%) expressed both MOR-1 and CXCR4 at the cell surface (Figure 2). Far fewer cells expressed MOR-1 or CXCR4 exclusively (2% and 3% of counted cells, respectively), and 8% of cells quantitated did not express either receptor.

Interestingly, on the surface of double-positive cells, the staining for the two receptors appears to overlap, suggesting the possibility of physical proximity. A proportion of these double-positive cells co-expressed CXCR4 and MOR-1 in distinct domains on the surface that traced the circumference of the nucleus. Additionally, double-positive cells that exhibited uniform distribution of expression of the two receptors across the cell surface differed in nuclei morphology. A similar co-localization pattern of MOR-1 and CXCR4 has been previously reported in cortical neurons [10]. Given the observed changes in nuclear morphology, we proceeded to determine whether these discrete domains were specific to MOR-1 and CXCR4 or resulted from general TF-1 cellular topography. To distinguish between these two possibilities, fluorescently tagged amphipathic molecules that embed within regions of high lipid density were used to visualize the plasma membrane. This procedure clearly demonstrated that the observed discrete domains were regions of high lipid density (Figure 3A), likely owing to membrane thinning and nuclear dispersion during M phase of the cell cycle.

Together these observations suggest a possible link between cell cycle and the observed MOR-1 and CXCR4 surface localization patterns. To better understand the influence of the phase of the cell cycle on MOR-1 and CXCR4 cell surface localization, TF-1 cells were treated with aphidicolin (10 μg/ml) for 16 hours to induce an arrest in early S phase. Following treatment, MOR-1 expression was analyzed on the surface of TF-1 cells in S phase using fluorescent microscopy and flow cytometry.
TF-1 cells in S phase expressed MOR-1 in a punctate pattern across the cell surface (Figure 3B) and expressed MOR-1 at a higher mean fluorescent intensity (MFI) than the untreated, heterogeneous population of TF-1 cells (Figure 3C). These observations suggested that the diverse cell surface expression patterns of MOR-1 in conjunction with CXCR4 are the result of a specific phase of the cell cycle. While the two receptors are expressed in overlapping membrane domains, suggesting the possibility of proximity, the localization in discrete membrane domains surrounding the nucleus may not be due to regulated trafficking of the two receptors.

Effects of prolonged DAMGO exposure on CXCR4 expression

To study the effects of MOR-1 signaling on CXCR4 expression, the levels of total as well as surface CXCR4 were examined in DAMGO-pretreated TF-1 cells. Western immunoblot analyses were performed on whole cell lysates prepared from TF-1 cells, in the absence or presence of two different concentrations of DAMGO (1 and 10 μM), a specific MOR-1 agonist. Total levels of CXCR4 protein (glycosylated CXCR4 monomer detected at ~50 KDa) remained unchanged, suggesting that DAMGO treatment does not affect overall expression or stability of the CXCR4 protein within the cell (Figure 4A). This observation prompted studies to determine whether the subcellular localization of CXCR4 was affected by DAMGO treatment. Immunostaining for surface CXCR4 was performed on nonpermeabilized TF-1 cells and analyzed by flow cytometry. Untreated TF-1 cells displayed a distribution among a range of MFIs, with three distinct cellular populations: a large population of CXCR4 non-expressing cells, a low-expressing cell population, and a smaller population of CXCR4 high-expressing cells (Figure 4B). This is consistent with the heterogeneity in CXCR4 expression observed in the human hematopoietic stem cell compartment [15] and is consistent with levels of CXCR4 surface expression.
expression in primary human bone marrow cells. DAMGO (1 and 10 μM) pretreatment for 24 hours resulted in an alteration in the relative proportion of CXCR4+ cells toward the low-expressing phenotype, which was evident from an increase in the low-expressing (midrange) MFI peak and a reduction in both the non-expressing and high-expressing MFI peaks. Collectively, these studies show that total protein levels of CXCR4 remain unchanged, while surface expression levels of CXCR4 are altered following DAMGO exposure.

Effects of prolonged DAMGO exposure on HIV-1 replication in TF-1 cells
Given the observed changes in the level of CXCR4 surface expression following DAMGO treatment and the understanding that co-receptor expression levels correlate with cell susceptibility to HIV-1 infection [16], the level of impact DAMGO would have on HIV-1 replication was of interest. HIV-1 core antigen (p24) assays were used to assess HIV-1 replication in TF-1 cells in the presence of DAMGO. In comparison with untreated cells, DAMGO pretreatment for 24 hours resulted in a dose-dependent decline in p24 production (Figure 5). Specifically, p24 levels dropped from 885 ng/ml in untreated cells to 386 ng/ml in cells treated with DAMGO at 1 μM (p < 0.001) and 254 ng/ml in cells treated with DAMGO at 10 μM (p < 0.001). This decline, which ranged from 2.3- to 3.5-fold, was partially reversed upon CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH) pretreatment to 763 ng/ml (p < 0.001). Altogether, the results suggested that exposure to μ-opioids might render bone marrow progenitor cell populations less susceptible to HIV-1 infection.

Discussion
Because HIV-1 has been reported to penetrate the bone marrow [17,18] of infected patients, it has been suggested that cellular subsets of this important compartment may serve as reservoirs for the virus. We aimed to determine the effects of the specific MOR-1 agonist DAMGO on viral replication in human bone marrow progenitor cells. The human CD34+/CD38− TF-1 bone marrow-derived hematopoietic progenitor cell line was used as an in vitro model because it is known to express the HIV-1 receptor CD4 as well as the co-receptor CXCR4.

MOR-1 is the most extensively characterized receptor subtype of the family and it has been identified on terminally differentiated mature immune cell populations, including human CD4+ cells, cells of the monocyte-macrophage lineage [19], and more primitive CD34+38− peripheral blood and cord blood stem cells [20]. Its presence on more terminally differentiated progenitor cells and the concomitant underlying significance of its presence have, however, not been fully elucidated. In this regard, we have clearly demonstrated the presence of MOR-1 in a TF-1 human bone marrow progenitor cell population.

MOR-1 has also been shown to oligomerize with other G protein–coupled receptors (GPCRs) such as the chemokine co-receptor CCR5 [21] with an adverse impact observed on the G-protein coupling of the other oligomerization...
partner. Alterations in G-protein coupling, differential affinity of specific agonists, and enhanced internalization have also been reported for the \( \mu \)–\( \delta \) opioid receptor (MOR-DOR) hetero-oligomeric complex [22]. Therefore, the presence of MOR-1 and CXCR4 in overlapping domains on TF-1 cells leaves open the possibility of dimerization between these receptors. Such localization of MOR-1 has also been reported in neuronal membranes of the rat caudate putamen wherein \( \mu \)-opioid receptors were found in cholesterol and sphingolipid-rich membrane subdomains known as lipid rafts [20], where they seem to be important in regulation of GPCR signaling, receptor phosphorylation, and membrane trafficking [23]. This observation raises interesting questions concerning the biological significance of MOR-1 localization in TF-1 progenitor cells. The results reported herein have also revealed MOR-1-mediated alteration in surface CXCR4 levels, in line with our previous studies [10,11]. It has been previously reported that CXCR4 signaling is impeded by DAMGO in rat cortical neurons [10,11]. Therefore, future studies will be focused on investigating whether molecular events triggered by MOR-1 signaling affect CXCR4 receptor recycling and/or CXCR4 signaling in bone marrow progenitor cells.

These studies also provide a unique insight into the role of \( \mu \)-opioids in modulating HIV-1 replication in bone marrow progenitor cells. In the setting of HIV-1 infection, downregulation of CXCR4 might translate into a reduction in HIV-1 replication under the influence of \( \mu \)-opioids, thereby serving a protective function, as suggested in studies performed in macaques [24]. As shown here, DAMGO exposure resulted in a decrease in HIV-1 replication. While this decrease may be the result of a decrease in viral entry involving CXCR4, the possibility remains that this decrease is the result of inhibition of post-entry events in the viral life cycle. Paradoxically, because the SDF-1–CXCR4 axis is vital for survival of progenitor cells [25], a reduction in
levels of CXCR4 might render them more susceptible to apoptosis in vivo. This result might provide a plausible explanation for the hematopoietic dysregulation observed in animal models of long-term morphine administration [26-29]. These results warrant further studies aimed at dissecting the divergent and dichotomous effects of \( \mu \)-opioids on terminally differentiated cell populations in the peripheral blood and bone marrow.

**Figure 4** DAMGO alters surface expression of CXCR4 on TF-1 cells. (A) Total levels of CXCR4 remain unaltered in TF-1 cells upon DAMGO treatment. Western immunoblot analyses performed with TF-1 cell line whole cell lysates demonstrate the presence of glycosylated CXCR4 monomer at 45 KDa. In comparison to the untreated cells, DAMGO (1 and 10 \( \mu \)M)-treated cells exhibited a similar density of CXCR4, indicating that CXCR4 expression at the protein level does not change. The membrane was stripped and reblotted for human \( \beta \)-actin (43 KDa) as the endogenous loading control. (B) Treatment of TF-1 cells with DAMGO results in a shift in CXCR4\(^+\) cells to the low-expressing phenotype. Immunofluorescence flow cytometry analysis of nonpermeabilized TF-1 cells was performed to detect a change in surface expression of CXCR4 following DAMGO treatment. Immunofluorescence analysis for surface CXCR4 by flow cytometry demonstrated that TF-1 cells were distributed among three populations, non-expressing cells, low-expressing cells (lower mean fluorescence intensity [MFI]), and high-expressing cells (higher MFI). DAMGO pretreatment (1 and 10 \( \mu \)M) for 24 hours resulted in a shift in the relative proportion of CXCR4\(^+\) cells to the low-expressing phenotype, as is evident from the increase in the lower MFI peak and the reduction in the higher MFI peak. CXCR4 antibody isotype controls are shown at the bottom.

**Figure 5** DAMGO treatment inhibits the replication of HIV-1 X4-utilizing strain IIIB in TF-1 cells. Analyses involving the detection of HIV-1 p24 capsid protein were performed on cellular supernatants 24 hours after infection to assess HIV-1 IIIB replication in response to DAMGO treatment of TF-1 cells. Absolute values of p24 levels are denoted in ng/ml on the Y axis. A 2.3-fold decrease was observed with DAMGO treatment (1 \( \mu \)M), which further declined to 3.5-fold at 10 \( \mu \)M. CTAP pretreatment reversed DAMGO-mediated decline in p24 levels. Samples were assayed in triplicate and results shown are the average of two independent experiments. *\( p = 0.00012 \), **\( p = 0.00000076 \), and *** \( p = 0.000002 \).

**Conclusions**

These studies have demonstrated the presence of both MOR-1 and CXCR4 on the cell surface of the hematopoietic progenitor cell line TF-1. Additionally, these receptors are localized to regions of high hydrophobicity within the membrane, indicative of high lipid density. As such, MOR-1 and CXCR4 are localized in proximity in this cell population. Most importantly, these experiments demonstrate the alteration in surface expression of CXCR4 as a result of DAMGO stimulation, and reduction in HIV-1 replication of a CXCR4-utilizing (X4) viral strain.

**Methods**

**Materials**

The potent cAMP phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine was obtained from Sigma-Aldrich (St. Louis, MO). DAMGO, a selective \( \mu \)-opioid peptide, and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP), a selective MOR antagonist, were purchased from Sigma-Aldrich. Amicon Ultra-0.5, Ultracel-3 Membrane, 3-kDa centrifugal filters for protein purification were obtained from Millipore (Bellerica, MA). Whole cell lysates were prepared for protein studies in radioligand binding with L-[\( ^3 \)H]GABA and in tissue binding with [\( ^3 \)H]dopamine (Pierce ECL) and [\( ^3 \)H]glutamate (Thermo Fisher Scientific, Rockford, IL), and protein concentrations were calculated using the bicinchoninic acid (BCA) protein assay as described by the manufacturer (Pierce ECL).
Cell culture and treatment procedures

The TF-1 CD34+38+ cell line (American Type Culture Collection [ATCC], Manassas, VA) was grown in TF-1 media which is composed of RPMI-1640 medium (ATCC; Mediatech, Inc., Manassas, VA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Thermo Fisher Scientific, Logan, UT), penicillin (100 U/ml), streptomycin (100 μg/ml), and recombinant human granulocyte/macrophage colony-stimulating factor (2 ng/ml) (eBioscience, San Diego, CA). The SH-SY5Y human neuroblastoma cell line (ATCC) was propagated in a 1:1 mixture of Eagle’s minimal essential medium with Earle’s salts, L-glutamine, and F-12 K nutrient mixture (Mediatech) supplemented with 10% heat-inactivated FBS (HyClone), penicillin (100 U/ml), and streptomycin (100 μg/ml). The cells were maintained at 37°C in 5% CO₂ at 90% relative humidity.

Western immunoblot analysis

To identify MOR-1 at the protein level, an N-terminus-specific antibody was used that recognizes a region mapping within the extracellular domain of human MOR-1 (N-20, Santa Cruz Biotechnology, Santa Cruz, CA). To demonstrate the specificity of interaction, assays were performed under nonblocking and blocking conditions. Whole cell lysates were prepared in RIPA buffer (Pierce ECL) and used to determine protein concentrations utilizing the BCA protein assay as described by the manufacturer (Pierce ECL). An equal amount of protein was run on a 10% sodium dodecyl sulfate–polyacrylamide gel and transferred to a 0.45-μm Immobilon-P polyvinylidene fluoride membrane followed by probing with the MOR-1 polyclonal antibody and detecting with a horseradish peroxidase (HRP)-conjugated antigoat IgG antibody (Jackson ImmunoResearch Laboratories). Subsequently, CXCR4 was labeled with an N-terminus-specific phycoerythrin-conjugated antihu- man CXCR4 monoclonal antibody, 1D9 (Pharmingen, BD Biosciences, San Jose, CA), followed by secondary staining with a rhodamine (TRITC)-conjugated antirat IgG antibody (Jackson ImmunoResearch Laboratories). Each step was accompanied by washing three times with PBS. Negative controls (not shown) consisted of “no primary” and “isotype primary” antibody conditions. Cells were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA) and observed under an Olympus IX81 deconvolution microscope at 60x magnification. A total of 1000 cells were counted following three independent staining experiments, and the percentage of cells in each phenotype was calculated based on the total number of cells counted. Averages reported were calculated based on the three independent experiments, and error bars represent the standard deviation of the results.

Immunofluorescence analysis

To examine cellular distribution of MOR-1 and to compare the expression pattern of MOR-1 with that of CXCR4 on the surface of TF-1 cells, immunofluorescence studies were performed. Cells were incubated on poly-D-lysine-coated coverslips. Where indicated, cells were treated for 16 hours with aphidicolin (10 μg/ml) to arrest cells in early S phase. Cells were subsequently fixed with 2% followed by 4% paraformaldehyde. So that we could visualize the surface expression of the two receptors, TF-1 cells were not permeabilized prior to staining. Sequential staining began with primary labeling with an N-terminus-specific MOR-1 antibody, N-20 (Santa Cruz Biotechnology), followed by secondary labeling with a fluorescein isothiocyanate-conjugated antigoat IgG antibody. Subsequently, CXCR4 was labeled with an N-terminus-specific phycoerythrin-conjugated antihu- man CXCR4 monoclonal antibody, 1D9 (Pharmingen, BD Biosciences, San Jose, CA), followed by secondary staining with a rhodamine (TRITC)-conjugated antirat IgG antibody (Jackson ImmunoResearch Laboratories).

Flow cytometry

To determine mean fluorescence intensity of surface CXCR4 on TF-1 cells, the cells were serum starved for 1 hour, then resuspended in TF-1 serum free media. Aliquots of 5 x 10⁵ cells were incubated in the absence or presence of two different concentrations of DAMGO (1 and 10 μM) for 24 hours. These concentrations were selected because 10 μM represents the upper range of morphine observed in the serum of morphine-dependent animals [31]. With respect to the MOR-1 analysis, where indicated, cells were incubated in the absence or presence of aphidicolin (10 μg/ml) for 16 hours to arrest cells in early S phase. Collected cells were then washed with
FACS wash buffer (Hanks balanced saline solution [Mediatech], 3% FBS, and 0.02% NaN3). So that we could visualize the surface expression of the two receptors, TF-1 cells were not permeabilized prior to staining. Cells were then reacted with a titrated amount of a monoclonal phycoerythrin-conjugated anti-human CXCR4 antibody 12G5 (R & D Systems, Minneapolis, MN) or MOR-1 (N-20, Santa Cruz Biotechnology) on ice for 30 minutes. Concentration-matched IgG2A isotype or whole IgG control antibody preparations were used as negative controls. Subsequently, cells were again washed with FACS wash buffer and fixed with 1% paraformaldehyde. We performed flow cytometry using a FACSCalibur Flow Cytometer (BD Biosciences) and analyzed the results using FlowJo version 6.1.1 software (Tree Star, Ashland, OR).

HIV-1 p24 ELISA
To assess the effects of DAMGO pretreatment on HIV-1 replication in TF-1 cells, p24 assays for measuring viral core antigen were performed. Cells were seeded into 12-well plates at a density of 0.5 × 10^6 cells/ml and pretreated for 24 hours with DAMGO (1 or 10 μM) alone or DAMGO (10 μM) and CTAP (1 μM) in TF-1 serum free media. After 24 hours, treated cells were seeded in a new 12-well plate at a concentration of 0.5 × 10^6 cells/ml/well. This step was followed by exposure to the X4-utilizing (X4) HIV-1 IIIB strain at a titer of 10^5 median tissue culture infective dose (TCID_50) (Advanced Biotechnologies, Inc., Columbia, MD). Two hours after infection, cells were washed with PBS, resuspended in TF-1 media containing serum, and reseeded in 12-well plates. Following incubation for 24 hours, the supernatant was collected and assayed for p24 core antigen using an Alliance p24 ELISA procedure as described by the manufacturer (Perkin Elmer, Waltham, MA). All samples were assayed in triplicate and p24 values were normalized for 1 × 10^6 cells/ml.

Statistical analysis
Significance was determined using the student t-test, considering p values of <0.05 significant.

Abbreviations
BCA: Bicinchoninic acid; CTAP: D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Phe-NH2; DAMGO: D-Ala2,N-Me-Phe4,Gly5-ol-enkephalin; DARP: 4’7’-diamidino-2-phenylindole; FBS: Fetal bovine serum; FITC: Fluorescein isothiocyanate; HRP: Horseradish peroxidase; MFI: Mean fluorescent intensity; MOR-1: μ-opioid receptor-1; PBS: Phosphate-buffered saline; SV: Simian immunodeficiency virus.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MS performed the experiments in Figures 1B and C, 2, and 3, participated in the design of the study, and drafted the manuscript. AB performed experiments in Figures 1A and 4A and participated in design of the study and in writing the first draft of the manuscript. AA performed experiments in Figure 4B. SRP performed experiments in Figure 5. OM participated in the design of the study. VP performed experiments in Figure 5 and participated in the design of the study. BW and MRN participated in design and coordination of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgments
These studies were funded in part by the Public Health Service, National Institutes of Health, through grants from the National Institute of Mental Health Comprehensive NeuroAIDS Core Center (CNAC) Developmental Grant, 1P30 MH-092177-01A (Nonnemacher, principal investigator), National Institute of Neurological Disorders and Stroke, NS32092 and NS46263, the National Institute of Drug Abuse, DA19807 (Wigdahl, principal investigator), DA15014 and DA32444 (Meucci, principal investigator), and under the Ruth L. Kirschstein National Research Service Award ST32MH079785 (Rappaport, principal investigator NIH Award to Temple University and Wigdahl, principal investigator of subcontract from Temple University to Drexel University). The contents of the paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Author details
1Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N. 15th Street, MS# 1013A, Philadelphia, PA 19102, USA.
2Center for Molecular Virology and Translational Neuroscience, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
3Center for Neuroimmunology and CNS Therapeutics, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
4Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.

Received: 6 August 2014 Accepted: 14 October 2014
Published: 23 October 2014

References
1. McCarthy L, Wetzl M, Sliker JK, Eisenstein TK, Rogers TJ: Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001, 62:111–123.
2. Wang J, Barke RA, Charboneau R, Roy S: Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005, 174:426–434.
3. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr: Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990, 4:869–873.
4. Steele AD, Henderson EE, Rogers TJ: Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 2003, 309:99–107.
5. Guo CJ, Li Y, Tian S, Wang X, Douglas SD, Ho WZ: Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Invest Med 2002, 50:435–442.
6. Chuang Ry, Suzuki S, Chuang TK, Miyagi T, Chuang LF, Dui RH: Opioids and the progression of simian AIDS. Front Biosci 2005, 10:1666–1677.
7. Kumar R, Orsoni S, Noman L, Verma AS, Tirado G, Giavedoni LD, Stappans S, Miller GM, Such SJ, Kumar A: Chronic morphine exposure causes pronounced virus replication in cerebral compartment and accelerated onset of AIDS in SIV/SHIV-infected Indian rhesus macaques. Virology 2003, 354:192–206.
8. Donahoe RH, Vahoh D: Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998, 83:87–87.
9. Suzuki S, Chuang AJ, Chuang LF, Dui RH, Chuang CY: Morphine promotes simian acquired immunodeficiency syndrome virus replication in monkey peripheral mononuclear cells: induction of CC chemokine receptor 5 expression for virus entry. J Infect Dis 2002, 185:1826–1829.
10. Patel JP, Sengupta R, Bardi G, Khan MZ, Mullen-Przeworski A, Meucci O: Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol 2006, 12:492–500.
11. Sengupta R, Barbassi S, Shimizu S, Cappello S, Vallee RB, Rubin JB, Meucci O: Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons. J Neurosci 2009, 29:2534–2544.
12. Kitamura T, Tange T, Terasawa T, Chiba S, Kureki T, Miyagawa K, Piao YF, Miyazono K, Uraibe A, Takaku F: Establishment and characterization of a
unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989, 140:323–334.

13. Alexaki A, Quiterio SJ, Nonnemacher MR, Liu Y, Banerjee A, Li L, Kilareski E, Widdahl B. Modeling bone marrow progenitor cell differentiation and susceptibility to HIV-1 infection. MOJ Immunology 2014, 1(2):10009.

14. Altmann DM, Clark AL, Kiss A, Hahn JW, Wesselmann R, Costea CI, Belcheva MM. Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. J Biol Chem 2006, 281:33749–33760.

15. Rosu-Myles M, Gallacher L, Murdoch B, Hess DA, Keeney M, Kelvin D, Dale L, Ferguson SS, Wu D, Fellows B, Bhatia M. The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. Proc Natl Acad Sci U S A 2000, 97:14626–14631.

16. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988, 242:919–922.

17. Regez RM, Klepool AE, Speekenbrink RG, Frissen PH. The risk of needle stick accidents during surgical procedures: HIV-1 viral load in blood and bone marrow. Int J STD AIDS 2005, 16:571–672.

18. McBrath MJ, Pruett JE, Cohn ZA. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc Natl Acad Sci U S A 1989, 86:675–679.

19. Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang Ry. Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun 1995, 216:922–930.

20. Huang P, Xu W, Yoon SI, Chen C, Chong PL, Unterwald EM, Liu-Chen LY. Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells. Brain Res 2007, 1184:46–56.

21. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY. Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 2004, 483:175–186.

22. Levac BA, ODowd BF, George SR. Oligomerization of opioid receptors: generation of novel signaling units. Curr Opin Pharmacol 2002, 2:76–81.

23. Chini B, Parenti M. G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 2004, 32:325–338.

24. Donahoe RM, Byrd LD, McClure HM, Fultz P, Brantley M, Marsteller F, Ansari AA, Wenzel D, Aceto M. Consequences of opiate-dependency in a monkey model of AIDS. Adv Exp Med Biol 1993, 335:21–28.

25. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Baurin P, Le Bousse-Kerdiles MC. Chemokine SDF-1 enhances circulating CD34+ cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000, 95:756–768.

26. Singhal PC, Reddy K, Franki N, Sanwal V, Gibbons N. Morphine induces spleenocyte apoptosis and enhanced mRNA expression of cathepsin-B. Inflammation 1997, 21:609–617.

27. Sei Y, Yoshimoto K, McIntyre T, Skolnick P, Acara PK. Morphine-induced thymic hypoplasia is glucocorticoid-dependent. J Immunol 1991, 146:194–198.

28. Freier DO, Fuchs BA. Morphine-induced alterations in thymocyte subpopulations of B6C3F1 mice. J Pharmacol Exp Ther 1993, 265:81–88.

29. Fuchs BA, Pruett SB. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opioid and glucocorticoid receptors. J Pharmacol Exp Ther 1993, 266:417–423.

30. Kiwell BM, Day DJ, McDonald FJ, Miller JR. Mu and delta opioid receptor immunoreactivity and mu receptor regulation in brainstem cells cultured from late fetal and early postnatal rats. Brain Res Dev Brain Res 2004, 1409:9–19.

31. Miyagi T, Chuang LF, Doi RH, Carlos MP, Torres JV, Chuang Ry. Morphine induces gene expression of CCR5 in human CEMx174 lymphocytes. J Biol Chem 2000, 275:31305–31310.